Transdermal Drug Delivery Systems Market By Type (Transdermal Patches, Transdermal Semisolids) By Indication (Hormonal Disorder, Cardiac Disorder, Migraine, Others) By End-user (Home Care Settings, Hospitals, and Clinics) Regional Analysis & Forecast - 2026

Introduction

Transdermal drug delivery system is defined as self-contained, discrete dosage form which when applied to intact skin deliver the drug through the intact skin at a controlled rate to the systemic circulation and maintain the drug concentration within the therapeutic window for a prolonged period of time. Recently, the use of transdermal patches for pharmaceuticals is limited because only a few drugs have proven to be effectively delivered through the skin. TDDS is the alternative route of administration for the patients who cannot tolerate oral dosage forms such as vomiting patient.

Market Overview

The Global Transdermal Drug Delivery Systems Market was valued at $ XX Mn in 2018 and is forecast to grow at XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The rise in geriatric population and upsurge in a number of patients suffering from chronic disorders are expected to drive the market growth. Moreover, the increase in adoption of third-generation transdermal drug delivery systems, such as iontophoresis, boosts the market growth. However, the disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth. According to a CADI Research Foundation, hypertension is the most prevalent disease in India. It is evident from the fact that the number of people with hypertension is projected to increase to 214 million in 2025 from 118 million in 2000.

Transdermal Drug Delivery Systems depending on the Type, matrix patch segment is expected to account for the largest share of the Transdermal Drug Delivery Systems market. The matrix patch incorporates the drug into an adhesive polymer matrix, from which the drug is continuously released into the skin. The dose of drug delivered depends on the amount of drug held in the matrix and the area of the patch applied to the skin.

Key Developments:

• In January 2018, Hisamitsu Pharmaceutical (Japan) launched ALLESAGA TAPE in the Japanese market


• In July 2018, UCB (Belgium) received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration (CFDA)


• In August 2018, Luye Pharma (China) signed an agreement with Bayer AG (Switzerland) to acquire the global rights to the Apleek contraceptive transdermal patch

Segmentation

The global Transdermal Drug Delivery Systems Market is segmented on the basis of Type, Indication, End-user, and region.

Based on the Type: Transdermal Patches and Transdermal Semisolids.

Based on the Indication:Hormonal disorder, Cardiac disorder, Migraine, Parkinson Disease, Alzheimer’s, HIV, Osteoporosis, Dermatological disease

Based on End-user: Home Care Settings, Hospitals, and Clinics

Based on the region: North America, Asia-Pacific, Europe, and LAMEA. North America is considered as the biggest market of Transdermal drug delivery systems. Moreover, the presence of main pharmaceutical organizations in these regions has decidedly affected the development of the market. Nations, for example, the US, Canada, Mexico, have represented a solid interest of idiopathic pulmonary fibrosis therapeutics credited to the expanding number of IPF rate happening in these nations.